UP­DATE: Will Bio­gen ever pub­lish the tri­al re­sults for its new Alzheimer’s drug?

Usu­al­ly when a new drug is ap­proved by the FDA, physi­cians who might use that drug can turn to the med­ical lit­er­a­ture for a deep­er un­der­stand­ing of who ex­act­ly might ben­e­fit from it, what ex­act­ly oc­curred in the clin­i­cal tri­als (be­yond the com­pa­ny’s press re­lease), and why the agency signed off on it.

But in the case of Bio­gen’s new con­tro­ver­sial Alzheimer’s drug Aduhelm (ad­u­canum­ab), it’s un­clear if the com­pa­ny will go the ex­tra mile and try to pub­lish the da­ta, par­tic­u­lar­ly as the on­ly pos­i­tive da­ta was from a post-hoc analy­sis of one of the two tri­als that failed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER